BioCentury
ARTICLE | Clinical News

AXL1717: Phase II started

January 2, 2012 8:00 AM UTC

Axelar began an open-label Phase II trial comparing oral AXL1717 vs. docetaxel in about 140 patients with previously treated, locally advanced or metastatic NSCLC. Sanofi (Euronext:SAN; NYSE:SNY, Par...